The Retatrutide Gold Rush: How America Started Selling a Drug That Isn’t Even on the Market Yet

 The Retatrutide Gold Rush: How America Started Selling a Drug That Isn’t Even on the Market Yet

Retatrutide may be one of the most anticipated weight-loss drugs in America.

There is just one problem:

It isn’t on the market yet.

As of September 2026, retatrutide remains an investigational drug being developed by Eli Lilly. It has produced impressive Phase 3 results, but it has not been approved by the FDA or any other regulatory agency.

Yet clinics, peptide companies, telehealth operators and online vendors are already selling products represented as retatrutide.

I wanted to understand what that market actually looks like from the other side.

What I found should make patients—and especially licensed medical professionals—ask some very basic questions.

Look at the Vial

For this article, I recreated the labeling from an actual product I reviewed while changing the branding so the supplier cannot be identified.

The vial contained white powder and was labeled:

16 mg

CLINIC USE ONLY

FOR IM OR SQ ONLY

There was also language concerning reconstitution, refrigeration and storage.

What wasn’t obvious was more important.

No patient name.

No prescribing physician.

No clearly identified dispensing pharmacy.

No conventional pharmacy prescription label.

No final concentration.

And no simple patient-specific directions explaining exactly how 16 mg of powder becomes an injectable medication.

That is a very different experience from receiving a conventional prescription drug from a licensed pharmacy.

Pharmacy Language Without a Pharmacy

Then I looked at the way the product was being presented to the medical professional.

One email described access to:

“WHOLESALE-PRICED PEPTIDES & HORMONES”

through a:

“USA-based, FDA-licensed/compliant CONSORTIUM of 503(A)(&(B) firms. 99+% Purity with COA.”

That wording should stop a medical professional for a second.

It uses almost every term capable of making the transaction sound pharmaceutical:

USA-based. FDA. 503A. 503B. COA. 99% purity.

But it still does not answer the simplest question:

What pharmacy is this?

Not “what consortium.”

Not “what firms.”

What licensed pharmacy or registered outsourcing facility actually made this specific vial, and under what lawful pathway did it reach the clinic?

That distinction is especially important here because FDA currently says retatrutide cannot be used in compounding under federal law.

This is one of the ways a seller that is not presenting itself as the actual dispensing pharmacy can make a relationship feel comfortable to a physician, NP, med spa or clinic.

It sounds like pharmacy.

It looks like pharmacy.

But instead of simply saying:

“We are XYZ Pharmacy. Here is our license. Here is the prescription. Here is your labeled medication.”

you get a “consortium of 503A and 503B firms.”

Those are not the same thing.

“99% Pure Shit”

And then there is the purity pitch.

“99+% Purity with COA.”

That should tell you something too.

When was the last time you called a legitimate pharmacy about a prescription medication and they tried to close you by saying:

“This is the good stuff. Ninety-nine percent pure shit.”

It sounds less like a pharmacy transaction and more like the cliché of somebody buying cocaine and the dealer assuring them:

“Trust me, man. This is pure shit.”

That may sound crude, but that is exactly why the comparison is useful.

A legitimate pharmacy does not need “99% pure” to substitute for its identity.

It leads with the pharmacy.

The prescription.

The labeled drug.

The concentration.

The patient or lawful office-use pathway.

The pharmacist.

The traceable source.

A COA can absolutely contain legitimate analytical testing information. The problem is when the COA and a purity percentage become the answer to questions they cannot answer.

A COA alone does not establish that the vial in your hand was the sample tested.

It does not establish sterility.

It does not establish lawful dispensing.

It does not tell you which pharmacy stood behind the finished product.

And it certainly does not turn an investigational molecule into something eligible for compounding.

“99% pure” is not a pharmacy license.

The IM Label Was Another Strange Detail

The vial also stated:

“FOR IM OR SQ ONLY.”

SQ means subcutaneous injection.

IM means intramuscular injection.

That immediately caught my attention.

The incretin-based weight-loss medications physicians are accustomed to using, including semaglutide and tirzepatide, are administered subcutaneously.

Retatrutide is also being studied by Lilly as a once-weekly subcutaneous injection.

So why is a vial represented as retatrutide being labeled for both intramuscular and subcutaneous use?

Maybe the seller has an explanation.

But it is another question a medical professional should be asking before a needle ever touches a patient.

Now You Have to Become a Pharmacist

The vial I reviewed wasn’t a ready-to-use liquid injection.

It was powder.

That means somebody has to reconstitute it.

Once you introduce bacteriostatic water or another diluent, another issue appears:

What is the final concentration?

If a vial contains 16 mg and somebody adds one volume of diluent, you have one concentration.

Add a different volume and you have another.

Then somebody has to translate the prescribed milligram dose into milliliters and ultimately into syringe markings.

And then that calculation changes again when a patient titrates.

A small misunderstanding can become a significant dosing error.

This is precisely why pharmacy labeling, dispensing instructions, concentration and traceability matter.

Medicine shouldn’t arrive as a chemistry project and a math problem.

This Isn’t Just a Gray Area

FDA’s current position is unusually direct:

Retatrutide cannot be used in compounding under federal law.

FDA says retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition. The agency has warned telehealth companies marketing it, API distributors supplying it to compounders and outsourcing facilities involved with retatrutide products.

Eli Lilly is equally clear.

The company says retatrutide remains investigational, has not been approved by any regulatory agency and is not yet available for public use.

This isn’t an argument about whether retatrutide is promising.

It is extremely promising.

That is exactly why a commercial market has developed before the medication itself has reached the market.

Three Questions I Would Ask

Forget the polished website for a minute.

Forget the vial design.

Forget the words FDA, 503A, 503B and 99% purity.

Ask three questions:

1. What licensed pharmacy or registered outsourcing facility made this exact vial?

2. What lawful pathway permits that facility to provide retatrutide today?

3. Can I independently verify the pharmacy, source, concentration and dispensing information associated with this specific product?

If those questions do not produce simple answers, another COA should not make the transaction feel safer.

The Bigger Story

Retatrutide itself may not even be the most interesting part of this story.

The distribution system forming around it is.

An investigational pharmaceutical molecule has already generated a commercial ecosystem before the actual drug has received regulatory approval.

Provider portals.

“Clinic use only” vials.

Powder requiring reconstitution.

Research-peptide terminology.

COAs.

“99% purity.”

Medical-looking labels.

References to FDA, 503A and 503B.

Everything can look just pharmaceutical enough that a licensed professional stops asking the most basic question:

Where did the medicine actually come from?

And that may be the lesson here.

If you’re a physician, NP, nurse, med-spa owner or clinic operator, don’t let sophisticated vocabulary do your due diligence for you.

A legitimate medical supply chain should become more transparent the closer you look at it—not less.

Retatrutide may eventually become one of the most important metabolic medications developed in years.

But enthusiasm for what this molecule may become should not lower the standard for what is being injected into patients today.

In medicine, legitimacy isn’t established by how professional the vial looks or how “pure” somebody says the powder is.

It’s established by whether you can trace exactly what’s inside it, who made it, who dispensed it and under what authority it reached the patient.

About the Author

AJ Pakpour is a healthcare entrepreneur, consultant, author and creator of The Business of Modern Medicine. His work spans medical practice development, physician integration, telemedicine, healthcare operations, pharmacy relationships, compliance infrastructure and emerging healthcare business models.

AJ Pakpour — Press, Research & Professional Profiles

Official Biography
https://www.ajpakpour.com/about

Press & Media Archive
https://www.ajpakpour.com/press

LinkedIn
https://www.linkedin.com/in/aj-pakpour-015538328

Google Scholar
https://scholar.google.com/citations?hl=en&user=CzoDaVIAAAAJ

Crunchbase
https://www.crunchbase.com/person/aj-pakpour

Medium — The Business of Modern Medicine
https://medium.com/the-business-of-modern-medicine

Substack — AJ Pakpour
https://substack.com/@ajpakpour

Bhikitia — AJ Pakpour Biography
https://en.bhikitia.org/wiki/AJ_Pakpour

US Press Association — Member 802085615
https://uspressassociation.com/user.php

Muck Rack
https://muckrack.com/ajpakpour

ORCID
https://orcid.org/0009-0006-4800-3421

Online News Association Member Directory
https://www.journalists.org/member-directory/aj-pakpour

ASIDE Healthcare Member Profile
https://www.asidehealthcare.org/members/ajdoctorstaffers-com/

National Network of Libraries of Medicine Profile
https://www.nnlm.gov/user/89012

Clarity.fm Expert Profile
https://clarity.fm/ajpakpour

Doctor Staffers
https://doctorstaffers.com

AmeraCell
https://ameracell.com

Primary Regulatory Sources

FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Eli Lilly — What to Know About Retatrutide
https://www.lilly.com/news/stories/what-to-know-about-retatrutide

This article is commentary and analysis for educational purposes and does not constitute medical or legal advice. Representative vial imagery associated with this article has been fictionalized to avoid identifying a specific supplier. Statements attributed to supplier materials are reproduced for purposes of commentary and analysis.